SI-BONE closed a US $20MM round of growth capital financing, led by new investor Arboretum Ventures with participation from all of SI-BONE’s existing major investors.
Proceeds will support expansion of U.S. sales, following recent decisions to cover MIS SI joint fusion by Blue Cross Blue Shield of Michigan, Geisinger Health Plan in Pennsylvania and First Coast Service Options in Florida. Additional proceeds will support R&D to develop new products to treat the SI joint.
SI-BONE’s last funding announcement occurred in 4Q15, with the closing of a $39.2MM credit facility .
Sources: SI-BONE, Inc.; ORTHOWORLD Inc.
SI-BONE closed a US $20MM round of growth capital financing, led by new investor Arboretum Ventures with participation from all of SI-BONE's existing major investors.
Proceeds will support expansion of U.S. sales, following recent decisions to cover MIS SI joint fusion by Blue Cross Blue Shield of Michigan, Geisinger Health Plan...
SI-BONE closed a US $20MM round of growth capital financing, led by new investor Arboretum Ventures with participation from all of SI-BONE’s existing major investors.
Proceeds will support expansion of U.S. sales, following recent decisions to cover MIS SI joint fusion by Blue Cross Blue Shield of Michigan, Geisinger Health Plan in Pennsylvania and First Coast Service Options in Florida. Additional proceeds will support R&D to develop new products to treat the SI joint.
SI-BONE’s last funding announcement occurred in 4Q15, with the closing of a $39.2MM credit facility .
Sources: SI-BONE, Inc.; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.